Cantor Fitzgerald Boosts Earnings Estimates for Humana

Humana Inc. (NYSE:HUM) – Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for shares of Humana in a note issued to investors on Wednesday, February 12th. Cantor Fitzgerald analyst S. James now expects that the insurance provider will post earnings of $16.27 per share for the year, up from their previous forecast of $16.17. Cantor Fitzgerald currently has a “Neutral” rating and a $290.00 target price on the stock. The consensus estimate for Humana’s current full-year earnings is $16.11 per share.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%.

HUM has been the subject of a number of other reports. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and upped their price target for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. TD Cowen boosted their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Morgan Stanley cut their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 price target on shares of Humana in a report on Wednesday. Finally, Barclays raised their price objective on Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 22nd. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $292.26.

Humana Trading Up 1.0 %

NYSE HUM opened at $259.93 on Thursday. Humana has a 12 month low of $213.31 and a 12 month high of $406.46. The stock has a 50-day simple moving average of $272.44 and a 200 day simple moving average of $295.47. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $31.30 billion, a PE ratio of 23.02, a P/E/G ratio of 2.11 and a beta of 0.56.

Institutional Trading of Humana

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Pinnacle Wealth Management Advisory Group LLC grew its stake in Humana by 3.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after purchasing an additional 37 shares in the last quarter. Atlas Brown Inc. boosted its holdings in shares of Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after buying an additional 38 shares during the last quarter. Moors & Cabot Inc. grew its stake in shares of Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after buying an additional 40 shares in the last quarter. Mather Group LLC. increased its holdings in Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock worth $60,000 after buying an additional 41 shares during the last quarter. Finally, Capital Advisors Ltd. LLC increased its holdings in Humana by 26.1% during the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock worth $53,000 after buying an additional 43 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.